Abstract
Prior to 2004, the uro-oncology community viewed the management of advanced or metastatic prostate cancer with an air of resigned nihilism. Now, the range of therapeutic options available is the subject of ongoing debate and the British Uro-oncology Group (BUG) is collating oncologist opinions on the future management of castration-sensitive disease. Historically, treatment for metastatic prostate cancer was limited to androgen deprivation therapy (ADT) with the aims of delaying disease progression and palliating symptoms. Patients invariably progressed, developing castration-resistant disease with limited effective therapeutic options. This article is protected by copyright. All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
